Eschler Asset Management’s Immunocore IMCR Stock Holding History

Eschler Asset Management’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-80,000	Closed	-$2.41M	–	41
2026 Q1	$2.41M	Hold	80,000	–	–	2.4%	10
2025 Q4	$2.78M	Buy	80,000 +40,000	+100%	+$1.41M	1.87%	14
2025 Q3	$1.45M	Hold	40,000	–	–	1.08%	15
2025 Q2	$1.26M	Buy	+40,000	New	+$1.24M	0.95%	24
2024 Q3	–	Sell	-40,000	Closed	-$2.6M	–	75
2024 Q2	$2.6M	Hold	40,000	–	–	2.04%	12
2024 Q1	$2.6M	Hold	40,000	–	–	1.68%	15
2023 Q4	$2.73M	Buy	40,000 +10,000	+33%	+$520K	2.17%	10
2023 Q3	$1.56M	Sell	30,000 -4,000	-12%	-$237K	1.82%	13
2023 Q2	$2.04M	Sell	34,000 -26,000	-43%	-$1.48M	2.89%	7
2023 Q1	$2.97M	Buy	60,000 +28,000	+88%	+$1.57M	2.34%	13
2022 Q4	$1.83M	Buy	32,000 +12,000	+60%	+$675K	3.46%	8
2022 Q3	$939K	Buy	+20,000	New	+$953K	2.07%	16

Other funds holding IMCR

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Eschler Asset Management's IMCR Position: Q2 2026 in Review

Eschler Asset Management sold out of Immunocore (IMCR) in Q2 2026, closing a stake of 80,000 shares — an estimated $2.41M sold.

Eschler Asset Management first reported a position in IMCR in Q3 2022 and held it in 12 quarters. The position peaked at $2.97M in Q1 2023. 135 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

Eschler Asset Management reported no remaining Immunocore position as of Q2 2026 after selling out during the quarter.
Eschler Asset Management sold 80,000 Immunocore shares in Q2 2026, an estimated $2.41M.
Eschler Asset Management first reported a position in Immunocore in Q3 2022 and held it in 12 quarters.
Eschler Asset Management's Immunocore position peaked at $2.97M in Q1 2023.
135 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on Eschler Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.